日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CETSA-MS unveils novel targets engaged by rigosertib to promote anti-tumor activity and inflammatory responses.

CETSA-MS 揭示了 rigosertib 促进抗肿瘤活性和炎症反应的新靶点

Kechagioglou Petros, Yurugi Hajime, Dupont Camille, Chernobrovkin Alexey, Romero Rossana, Harms Gregory, Oster Marie, Ciesek Sandra, Tweedell Rebecca, Kanneganti Thirumala-Devi, Zimmer Stefanie, Cosenza Stephen, Fruchtman Steven M, Rajalingam Krishnaraj

Proceedings of the fifth international RASopathies symposium: When development and cancer intersect

第五届国际RAS病研讨会论文集:当发育与癌症交汇

Rauen, Katherine A; Schoyer, Lisa; Schill, Lisa; Stronach, Beth; Albeck, John; Andresen, Brage S; Cavé, Hélène; Ellis, Michelle; Fruchtman, Steven M; Gelb, Bruce D; Gibson, Christopher C; Gripp, Karen; Hefner, Erin; Huang, William Y C; Itkin, Maxim; Kerr, Bronwyn; Linardic, Corinne M; McMahon, Martin; Oberlander, Beverly; Perlstein, Ethan; Ratner, Nancy; Rogers, Leslie; Schenck, Annette; Shankar, Suma; Shvartsman, Stanislav; Stevenson, David A; Stites, Edward C; Stork, Philip J S; Sun, Cheng; Therrien, Marc; Ullian, Erik M; Widemann, Brigitte C; Yeh, Erika; Zampino, Giuseppe; Zenker, Martin; Timmer, William; McCormick, Frank

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

在随机对照 III 期试验中,对接受利戈塞替尼治疗与最佳支持治疗的骨髓增生异常综合征患者进行低甲基化药物治疗失败后预后模型的验证

Nazha, Aziz; Sekeres, Mikkael A; Komrokji, Rami; Steensma, David P; Kantarjian, Hagop; Roboz, Gail; Fenaux, Pierre; Prebet, Thomas; Azarnia, Nozar; Zbyszewski, Patrick S; Fruchtman, Steven M; Santini, Valeria; Silverman, Lewis R; Platzbecker, Uwe; Garcia-Manero, Guillermo